- Data Reinforce Previous Clinical and Preclinical Studies
- Successfully Induced F-Protein Specific Neutralizing Antibody Response
- Phase 2 Studies to Begin in the Fourth Quarter of 2012
In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.
Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.